Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19257395 | 0.88 | CYP17A1 (0.37) | CYP17A1PTGES2BRAFCTSSCTSK | |
| SCHEMBL18595671 | 0.87 | CYP17A1 (0.41) | CYP17A1PTGES2BRAFCTSSCTSK | |
| SCHEMBL17996189 | 0.87 | PSIP1 (0.42) | PTGES2ALDH1A1HSD17B10POLBLMNA | |
| SCHEMBL18024066 | 0.84 | CYP17A1 (0.45) | CYP17A1BRAFCTSSCTSKADRA2A | |
| SCHEMBL19257097 | 0.77 | CYP17A1 (0.39) | CYP17A1BRAFCTSSCTSKADRA2A | |
| SCHEMBL18595673 | 0.75 | SLC22A12 (0.45) | CYP17A1CTSSCTSKLRRK2ALDH1A1 | |
| SCHEMBL17996190 | 0.72 | BRD4 (0.40) | ALDH1A1HSD17B10POLBLMNAPSIP1 | |
| SCHEMBL18024067 | 0.71 | CYP17A1 (0.46) | CYP17A1BRAFCTSSCTSKADRA2A | |
| SCHEMBL17946248 | 0.69 | HPGD (0.42) | BRAFALDH1A1HSD17B10LMNAHTT | |
| SCHEMBL18595670 | 0.68 | PSIP1 (0.45) | ALDH1A1HSD17B10LMNAPSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2020-03-24 | — | — | US | disclosed |
| US-9586949-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | CYP17A1 1111/4885PTGES2 3972/4885BRAF 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.